When median BAX/BCL2 value detected in AML-NK patients (0.62) was applied as a cut-off value for discriminating BAX/BCL2high and BAX/BCL2low group, 49% of patients had BAX/BCL2high status. Here, BCL2 is linked to acute myeloid leukemia.